...
mlys-img

Mineralys Therapeutics, Inc. Common Stock, Common Stock

MLYS

NSQ

$12.22

-$0.33

(-2.63%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$624.60M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
62.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.65 L
$16.91 H
$12.22

About Mineralys Therapeutics, Inc. Common Stock, Common Stock

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMLYSSectorS&P500
1-Week Return-4.31%-1.57%0.94%
1-Month Return-9.55%-1.86%5.38%
3-Month Return2.35%-6.07%10.61%
6-Month Return-9.41%-0.47%13.65%
1-Year Return79.71%10%33.13%
3-Year Return-23.62%10.67%32.44%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses2.94M18.73M31.48M84.66M[{"date":"2020-12-31","value":3.48,"profit":true},{"date":"2021-12-31","value":22.12,"profit":true},{"date":"2022-12-31","value":37.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(2.94M)(18.73M)(31.48M)(84.66M)[{"date":"2020-12-31","value":-294300000,"profit":false},{"date":"2021-12-31","value":-1872500000,"profit":false},{"date":"2022-12-31","value":-3147900000,"profit":false},{"date":"2023-12-31","value":-8465700000,"profit":false}]
Total Non-Operating Income/Expense(598.00K)(710.00K)1.68M23.13M[{"date":"2020-12-31","value":-2.59,"profit":false},{"date":"2021-12-31","value":-3.07,"profit":false},{"date":"2022-12-31","value":7.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(3.43M)(19.41M)(29.80M)(71.90M)[{"date":"2020-12-31","value":-342600000,"profit":false},{"date":"2021-12-31","value":-1940800000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-7189800000,"profit":false}]
Income Taxes115.00K27.00K(1.90M)(167.90K)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":23.48,"profit":true},{"date":"2022-12-31","value":-1656.07,"profit":false},{"date":"2023-12-31","value":-146,"profit":false}]
Income After Taxes(3.54M)(19.43M)(27.89M)(71.73M)[{"date":"2020-12-31","value":-354100000,"profit":false},{"date":"2021-12-31","value":-1943500000,"profit":false},{"date":"2022-12-31","value":-2789451500,"profit":false},{"date":"2023-12-31","value":-7173010500,"profit":false}]
Income From Continuous Operations(3.43M)(19.41M)(29.80M)(56.58M)[{"date":"2020-12-31","value":-342600000,"profit":false},{"date":"2021-12-31","value":-1940800000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-5658200000,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(3.43M)(19.41M)(29.80M)(71.90M)[{"date":"2020-12-31","value":-342600000,"profit":false},{"date":"2021-12-31","value":-1940800000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-7189800000,"profit":false}]
EPS (Diluted)--(1.74)(2.00)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-174,"profit":false},{"date":"2023-12-31","value":-200,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MLYS
Cash Ratio 8.42
Current Ratio 8.55

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MLYS
ROA (LTM) -38.56%
ROE (LTM) -61.19%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MLYS
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MLYS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.64
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Mineralys Therapeutics, Inc. Common Stock share price today?

Mineralys Therapeutics, Inc. Common Stock (MLYS) share price today is $12.22

Can Indians buy Mineralys Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Mineralys Therapeutics, Inc. Common Stock (MLYS) on Vested. To buy Mineralys Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MLYS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Mineralys Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Mineralys Therapeutics, Inc. Common Stock (MLYS) via the Vested app. You can start investing in Mineralys Therapeutics, Inc. Common Stock (MLYS) with a minimum investment of $1.

How to invest in Mineralys Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Mineralys Therapeutics, Inc. Common Stock (MLYS) via Vested in three simple steps:

  • Click on Sign Up or Invest in MLYS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Mineralys Therapeutics, Inc. Common Stock shares
What is Mineralys Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Mineralys Therapeutics, Inc. Common Stock (MLYS) is $16.91. The 52-week low price of Mineralys Therapeutics, Inc. Common Stock (MLYS) is $6.65.

What is Mineralys Therapeutics, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Mineralys Therapeutics, Inc. Common Stock (MLYS) is

What is Mineralys Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Mineralys Therapeutics, Inc. Common Stock (MLYS) is 2.64

What is Mineralys Therapeutics, Inc. Common Stock dividend yield?

The dividend yield of Mineralys Therapeutics, Inc. Common Stock (MLYS) is 0.00%

What is the Market Cap of Mineralys Therapeutics, Inc. Common Stock?

The market capitalization of Mineralys Therapeutics, Inc. Common Stock (MLYS) is $624.60M

What is Mineralys Therapeutics, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Mineralys Therapeutics, Inc. Common Stock is MLYS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top